These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9501893)

  • 21. Endocardial fibrosis associated with fenfluramine-phentermine.
    Fowles RE; Cloward TV; Yowell RL
    N Engl J Med; 1998 Apr; 338(18):1316. PubMed ID: 9565497
    [No Abstract]   [Full Text] [Related]  

  • 22. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine.
    Hensrud DD; Connolly HM; Grogan M; Miller FA; Bailey KR; Jensen MD
    Mayo Clin Proc; 1999 Dec; 74(12):1191-7. PubMed ID: 10593346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
    Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE
    N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anorectic therapy and valvular heart disease: a reappraisal.
    Silvestry FE; St John Sutton M
    Eur Heart J; 1999 Jul; 20(13):917-20. PubMed ID: 10361039
    [No Abstract]   [Full Text] [Related]  

  • 25. Anorectic-induced valvulopathy.
    Cheng TO
    Eur Heart J; 2000 Apr; 21(7):593-4. PubMed ID: 10775015
    [No Abstract]   [Full Text] [Related]  

  • 26. Studies confirm link between fen-phen and heart-valve disease.
    Harv Heart Lett; 1998 Dec; 9(4):4-6. PubMed ID: 9925979
    [No Abstract]   [Full Text] [Related]  

  • 27. Appetite suppressants and valvular heart disease.
    Devereux RB
    N Engl J Med; 1998 Sep; 339(11):765-6. PubMed ID: 9731094
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise.
    Weintraub M; Sundaresan PR; Schuster B; Ginsberg G; Madan M; Balder A; Stein EC; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):595-601. PubMed ID: 1587073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. US journal finds lower risk from diet pills.
    Josefson D
    BMJ; 1997 Nov; 315(7119):1329. PubMed ID: 9402766
    [No Abstract]   [Full Text] [Related]  

  • 30. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.
    Khan MA; Herzog CA; St Peter JV; Hartley GG; Madlon-Kay R; Dick CD; Asinger RW; Vessey JT
    N Engl J Med; 1998 Sep; 339(11):713-8. PubMed ID: 9731086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study.
    Weintraub M
    Clin Pharmacol Ther; 1992 May; 51(5):581-5. PubMed ID: 1445528
    [No Abstract]   [Full Text] [Related]  

  • 32. The fen-phen controversy: is regression another piece of the puzzle?
    Asinger RW
    Mayo Clin Proc; 1999 Dec; 74(12):1302-4. PubMed ID: 10593359
    [No Abstract]   [Full Text] [Related]  

  • 33. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine.
    Kancherla MK; Salti HI; Mulderink TA; Parker M; Bonow RO; Mehlman DJ
    Am J Cardiol; 1999 Dec; 84(11):1335-8. PubMed ID: 10614800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities.
    Jollis JG; Landolfo CK; Kisslo J; Constantine GD; Davis KD; Ryan T
    Circulation; 2000 May; 101(17):2071-7. PubMed ID: 10790349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Valvular heart disease associated with fenfluramine-phentermine.
    Connolly HM; Crary JL; McGoon MD; Hensrud DD; Edwards BS; Edwards WD; Schaff HV
    N Engl J Med; 1997 Aug; 337(9):581-8. PubMed ID: 9271479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The fenfluramine/phentermine combination for weight loss.
    Garrett SD; Cupp MJ
    Nurse Pract; 1997 Aug; 22(8):166, 168, 170. PubMed ID: 9279853
    [No Abstract]   [Full Text] [Related]  

  • 37. Morphology of anorexigen-associated valve disease by transthoracic and transesophageal echocardiography.
    Roldan CA; Gelgand EA; Decker P; Prasad A; Shively BK
    Am J Cardiol; 2002 Dec; 90(11):1269-73. PubMed ID: 12450616
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase.
    Weintraub M; Sundaresan PR; Schuster B; Averbuch M; Stein EC; Cox C; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):608-14. PubMed ID: 1587075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. After fen-phen.
    Cowley G; Springen K
    Newsweek; 1997 Sep; 130(13):46-8. PubMed ID: 10173270
    [No Abstract]   [Full Text] [Related]  

  • 40. Pregnancy outcomes after first trimester exposure to phentermine/fenfluramine.
    Jones KL; Johnson KA; Dick LM; Felix RJ; Kao KK; Chambers CD
    Teratology; 2002 Mar; 65(3):125-30. PubMed ID: 11877776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.